ArticlePsychopharmacology2006
Roles of pedunculopontine tegmental cholinergic receptors in brain stimulation reward in the rat.
Article in Psychopharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 38 citations in OpenAlex.
- The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and rescues synaptic/cognitive functions by modulating DRD1 signaling or directly binding to Abeta.Journal of neuroinflammation · 2024Article
- Characterization of three cholinergic inputs to the cochlear nucleus.Journal of chemical neuroanatomy · 2023Article
- Motor Synchronization to Rhythmic Auditory Stimulation (RAS) Attenuates Dopaminergic Responses in Ventral Striatum in Young Healthy Adults: [Frontiers in neuroscience · 2019Article
- Functional Connectivity of the Pedunculopontine Nucleus and Surrounding Region in Parkinson's Disease.Cerebral cortex (New York, N.Y. : 1991) · 2017Article
- Electron microscopic localization of M2-muscarinic receptors in cholinergic and noncholinergic neurons of the laterodorsal tegmental and pedunculopontine nuclei of the rat mesopontine tegmentum.The Journal of comparative neurology · 2016Article
- Revisiting the effect of nicotine on interval timing.Behavioural brain research · 2015Article
- Orexin-1 receptor antagonism does not reduce the rewarding potency of cocaine in Swiss-Webster mice.Brain research · 2012Article
- Biomarkers to optimize the treatment of nicotine dependence.Biomarkers in medicine · 2011Review
- Cholinergic cells of the pontomesencephalic tegmentum: connections with auditory structures from cochlear nucleus to cortex.Hearing research · 2011Review
- Multiple origins of cholinergic innervation of the cochlear nucleus.Neuroscience · 2011Article
- Cholinergic cells in the tegmentum send branching projections to the inferior colliculus and the medial geniculate body.Neuroscience · 2011Article
- Neuroimaging, genetics and the treatment of nicotine addiction.Behavioural brain research · 2008Review
- Dynamic changes in accumbens dopamine correlate with learning during intracranial self-stimulation.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThe brainstem pedunculopontine tegmental nucleus (PPTg) is proposed to mediate hypothalamic self-stimulation reward via cholinergic activation of the ventral tegmental area (VTA). However, to date there is little direct evidence to support this hypothesis.
objectivesTo further study the role of PPTg in hypothalamic self-stimulation reward.
methodsBy using in vivo microdialysis, the levels of extracellular acetylcholine (ACh) in the PPTg and VTA were detected during lateral hypothalamic (LH) self-stimulation in rats. Rate-frequency curve shift procedure was used to evaluate the effects of nonselective muscarinic antagonist scopolamine (1 approximately 100 microg/microl) and nicotinic antagonist mecamylamine (5 approximately 100 microg/microl) microinjected into the PPTg on the rewarding efficacy of LH self-stimulation. Subsequently, the drugs were injected into the PPTg, and the extracellular ACh in the VTA was measured.
resultsLH self-stimulation produced a concurrent ACh release in the PPTg and VTA. Intra-PPTg injection of scopolamine (100 microg/microl) significantly reduced the frequency threshold for LH self-stimulation reward, but nicotinic antagonist mecamylamine did not shift the threshold. However, mecamylamine (10, 25 microg/microl) injected into the PPTg robustly diminished the nicotine-potentiated LH self-stimulation reward. The extracellular ACh in the VTA was dramatically increased by intra-PPTg scopolamine (10, 100 microg/microl), but not by mecamylamine.
conclusionsResults confirm that PPTg plays an important role in brain stimulation reward by modulating the cholinergic activity of the VTA. The PPTg muscarinic receptors contribute to an inhibitory modulation of reward effects by self-stimulation, whereas nicotinic receptors seem to be more involved in nicotine potentiation of brain stimulation reward.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.